These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25154814)

  • 1. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
    Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
    Woo MG; Xue K; Liu J; McBride H; Tsang BK
    J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
    Yang XK; Wang JD; Wang SY; Zhang YX
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
    Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
    Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
    FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HtrA1 Down-regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway.
    Xiong Z; Fu Z; Shi J; Jiang X; Wan H
    Ann Clin Lab Sci; 2017 May; 47(3):264-270. PubMed ID: 28667026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
    Kong B; Wang Q; Fung E; Xue K; Tsang BK
    J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
    Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
    Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
    Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J; Zhang F; Li X; Liu Z
    Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E; Mills GB; Tsang BK
    Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
    Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
    J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
    Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
    Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.